Deutsche Bank Maintains a 'Buy' on Medicis (MRX); Aesthetics Tracking Well; Possible Upside from Pipeline / Business Development

Deutsche Bank maintains a 'Buy' on Medicis (NYSE: MRX), PT $40.

Deutsche analyst says, "The outlook for Medicis’ flagship Solodyn franchise has improved significantly – based on a strong switch thus far to the “new” protected doses and the key Q1 settlement with Teva. Hence, we continue to see MRX capable of generating longterm EPS growth of 12%+, driven by its acne and aesthetics brands, as well as its emerging development pipeline."

For more ratings news on Medicis click here and for the rating history of Medicis click here.

Shares of Medicis closed at $36.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Marex Group PLC (MRX) PT Raised to $90 at Keefe, Bruyette & Woods
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities